A Randomized Controlled Clinical Trial Comparing “Guideline Exposed” and “Guideline Naive” Physicians in Respect to Dosage Selection and Treatment Outcome with Doxepin in Depressive Disorders

Abstract

Introduction: Can prescribing of insufficient dosages and outcome of treatment with antidepressants in routine care be improved by guidelines?

Methods: 161 general practitioners and 162 psychiatrists in private practice documented 1319 patients, receiving doxepin for individual clinical reasons. Physicians were randomly divided into a guideline exposed and a control group. All physicians treated their patients according to individual clinical considerations.

Results: Average maximum daily dosage was 83 mg/d in the control and 95 mg/d in the intervention group (F=19.15; p<0). Only 3% of patients in both groups got the recommended dosage of 150 mg/d. Guideline exposure resulted in increased dosages preferably for milder forms of depression and in comparatively lower rates of improvement.

Conclusion: Guideline exposure did not reach its goal in respect to the recommended dosage. It missed its goal in respect to improvement of outcome and even showed negative effects. Guidelines should be evidence-based not only by referring to literature reviews but by testing their clinical effects in controlled clinical trials.

Key words

treatment guidelines - prescribing patterns - treatment algorithms - quality assurance - drug utilization observation study - tricyclic antidepressants - doxepin

References

• 1 Adli M, Berghofer A, Linden M, Helmchen H, Muller-Oerlinghausen B, Mackert A, Stamm T, Bauer M. Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study.  J Clin Psychiat. 2002;  63 782-790
• 2 Arzneimittelkommission der Deutschen Ärzteschaft . , (AKdÄ) Empfehlungen zur Therapie der Depression. , Arzneiverordnung in der Praxis, Sonderheft 5, AKdÄ 1997; 
• 3 Appleton WS. Fourth psychoactive drug usage guide.  J Clin Psychiat. 1982;  43 12-27
• 4 Azocar F, Cuffel B, Goldmann W, McCarter L. The impact of evidence-based guideline dissemination for the assessment and treatment of major depression in a managed behavioral health care organization.  J Behav Health Service Res. 2003;  30 109-118
• 5 Bridges PK. “…and a small dosage of an antidepressant might help”.  Brit J Psychiat. 1983;  142 626-628
• 6 Choudhry NK, Stelfox HAT, Detsky AS. Relationship between authors of clinical practice guidelines and the pharmaceutical industry.  JAMA. 2002;  287 612-617
• 7 Dimascio A, Meyer RE, Stifler L. Effects of Imipramine on individuals varying in level of depression.  Am J Psychiat. 1968;  124 55-58
• 8 Donoghue JA, Tylee A. The treatment of depression: prescribing patterns of antidepressants in primary care in the UK.  Brit J Psychiat. 1996;  168 164-168
• 9 Donoghue JA, Tylee A, Wildgust H. Cross-sectional database analysis of antidepressant prescribing in general practice in the United Kingdom.  Brit Med J. 1996;  313 861-862
• 10 Furukawa TA MH, Barbui C. Meta-analysis of effects and side effects of low dosage tricyclic antidepressants in depression: systematic review.  Brit Med J. 2002;  325 991-999
• 11 Gilmer WS, Trivedi MH, Rush AJ, Wisniewski SR, Luther J, Howland RH, Yohanna D, Khan A, Alpert J. Factors associated with chronic depressive episodes: a preliminary report from the STAR-D project.  Acta psychiat scan. 2005;  112 425
• 12 Helmchen H, Linden M. (Guest Editors) . Subthreshold disorders in psychiatry.  Comprehens Psychiat. 2000;  41 1-137
• 13 Ito H, Koyama A, Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription.  Brit J Psychit Brit J Psychiat tr. 2005;  187 243-247
• 14 Jerling M. Dosing of antidepressants - The unknown art.  J Clin Psychopharmacol. 1995;  15 435-439
• 15 Kjaergard LL, Als-Nielsen B. Association between competing interests and authors’ conclusions: epidemiological study of randomized clinical trials published in the BMJ.  Brit Med J. 2002;  325 249
• 16 Lieberman JA, Greenhouse J, Hamer RM, Krishnan KR, Nemeroff CB, Sheehan DV, Thase ME, Keller MB. Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy.  neuropsychopharmacology. 2005;  30 445-460
• 17 Linden M. Der Einfluss von Leitlinien, Standards und ökonomischen Vorgaben auf medizinische Entscheidungsprozesse.  Z ärztl Fortbild Qualität Gesundheitswesen. 2004;  98 200-205
• 18 Linden M. Leitlinien und die Psychologie medizinischer Entscheidungsprozesse bei der Behandlung depressiver Erkrankungen.  Fortsch Neurol Psychiat. 2005;  73 249-258
• 19 Linden M, Schuessler G. Low dosage antidepressant treatment in private practice - a replication study.  Pharmacopsychiatry. 1985;  18 44-45
• 20 Linden M, Helmchen H, Mackert A, Müller-Oerlinghausen B. Structure and feasibility of a standardized stepwise drug treatment regimen (SSTR) for depressed patients.  Pharmacopsychiatry. 1994;  27 51-53
• 21 Linden M, Ahrens B, Schotte K, Golde J. Der Einfluß von Richtlinienempfehlungen auf die Niedrigdosierung trizyklischer Antidepressiva am Beispiel von Doxepin.  Psychopharmakotherapie. 2000;  7 75-79
• 22 Linden M, Ludewig K, Munz T. Depressive Erkrankungen und antidepressive Therapie. Ein Vergleich von Nervenarztpraxis und psychiatrischer Klinik.  Nervenarzt. 2001;  72 521-528
• 23 Linden MLK, Munz T, Dierkes W. Dosage finding and outcome of venlafaxine treatment in psychiatric outpatients and inpatients. Results of a drug utilization observation study.  Pharmacopsychiatry. 2003;  36 197-205
• 24 McCombs JS, Nichol MB, Stimmel GL, Sclar DA, Beasley CM, Gross LS. et al . The cost of antidepressant drug therapy failure: A study of antidepressant use patterns in a medicaid population.  J Clin Psychiat. 1990;  51 60-69
• 25 MacDonald TM, McMahon AD, Reid IC, Fenton GW, McDevitt DG. Antidepressant drug use in primary care: A record linkage study in Tayside, Scotland.  Brit Med J. 1996;  313 860-861
• 26 Munizza C, Tibaldi G, Bollini P, Pirfo E, Punzo F, Gramaglia F. Prescription pattern of antidepressants in outpatient psychiatric practice.  Psychol Med. 1995;  25 771-778
• 27 Nunn CMH. Efficacy of antidepressant medication.  Brit J Psychiat. 2003;  183 463-464
• 28 Paykel ES HJ, Freeling P. et al . Predictors of therapeutic benefit from amitriptyline in mild depression: A general practice placebo-controlled trial.  J Affect Disord. 1988;  14 83-95
• 29 Paykel ES, Priest RG. Recognition and management of depression in general practice: consensus statement.  Brit Med J. 1992;  305 1198-1202
• 30 Perlis RH, Alpert J, Nierenberg AA, Mischoulon D, Yeung A, Rosenbaum JF, Fava M. Clinical and sociodemographic predictors of response to augmentation or dose increase among depressed outpatients resistant to fluoxetine 20 mg/day.  Acta psychiat scand. 2003;  108 432-438
• 31 Pincus HA, Marcus SC, Olfson M, Zarin DA, Thompson J. Prescribing trends in psychotropic medications: primary care, psychiatry, and other medical specialties.  JAMA. 1998;  279
• 32 Rao ML, Deister A, Laux G. et al . Low serum levels of tricyclic antidepressants in Amitriptyline- and doxepin-treated inpatients with depressive syndromes are associated with non-response.  Pharmacopsychiatry. 1996;  29 97-102
• 33 Schaaf B, Linden M, Weber HJ. An investigation of the representativity of neuropsychiatrists and their patients in a drug utilization observation study.  Pharmacopsychiatry. 1997;  30 44-51
• 34 Schneider F, Harter M, Brand S, Sitta P, Menke R, Hammer-Filipiak U, Kudling R, Heindl A, Herold K, Frommberger U, Elmer O, Hetzel G, Witt G, Wolfersdorf M, Berger M, Gaebel W. Adherence to guidelines for treatment of depression in in-patients.  Brit J Psychiat. 2005;  187 462-469
• 35 Schotte K, Linden M. Reasons for low-dosage treatment with antidepressants by psychiatrists and general practitioners.  J Pharmacoepidem Drug Safety. 2007;  , in press
• 36 Stewart JW, Quitkin FM, Klein DF. The pharmacotherapy of minor depression.  Am J Psychother. 1992;  46 23-26
• 37 Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stuart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackheim HA, Kupfer DJ, Luther J, Fava M. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps. A STAR^*D report.  Am J Psychiat. 2006;  163 1905-1917
• 38 Thiels C, Linden M, Grieger F, Leonhard J. Gender differences in routine treatment of depressed outpatients with the selective serotonin reuptake inhibitor sertraline.  Int Clin Psychopharmacol. 2005;  20 1-7
• 39 Toprac MG, Dennehy EB, Carmody TJ, Crismon ML, Miller AL, Trivedi MH, Suppes T, Rush AJ. Implementation of the Texas Medication Algorithm Project patient and family education program.  J Clin Psychiat. 2006;  67 1362-1372
• 40 Verdoux H, Begaud B. Pharmaco-epidemioloy: What do (and don’t) we know about utilization and impact of psychotropic medications in real life conditions.  Brit J Psychiat. 2004;  185 93-94
• 41 Wang PS, Schneeweiss S, Brookhart MA, Glynn RJ, Mogun H, Patrick AR, Avorn J. Suboptimal antidepressant use in the elderly.  J Clin Psychopharmacol. 2005;  25 118-126
• 42 Weiner J, Schumacher G. Psychotropic drug therapy knowledge of health care practitioners.  Am J Hosp Pharm. 1976;  33 237-241
• 43 World Health Organisation . Dosage effects of antidepressant medication in different populations A World Health organisation Collaborative Study.  J Affect Disord. 1986;  1-67

Correspondence